Whilst in BCC, DSG2 was shown to enhance downstream SHH signaling through the secretion of cytokines, upregulation of receptors (e.g., urokinase plasminogen activator surface receptor (uPAR) and interleukin (IL)-6R) and exosome secretion, leading to STAT3 phosphorylation and activation, and potentiating GLI1 expression (83). This evidence concerns the gene SHH and skin basal cell carcinoma.